{"abstract":"Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/08/12/2026-16440.html","cfr_references":[],"citation":"91 FR 52066","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":null,"disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2026-16440","effective_on":null,"end_page":52067,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/08/12/2026-16440.xml","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16440/nih-owned-invention-available-for-license-soluble-tissue-factor-a-novel-target-and-antibodies-for","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-16440?publication_date=2026-08-12","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-08-12/2026-16440/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":63,"last_updated":"2026-10-25 06:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16440.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16440.pdf?1786452318","publication_date":"2026-08-12","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/08/12/2026-16440.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2026-08-12T05:33:23Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":52066,"subtype":null,"title":"NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions","toc_doc":"NIH Owned Invention; Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.","topics":[],"type":"Notice","volume":91}